Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial

Abstract: There are no treatments available to slow or prevent the progression of Parkinson disease, despite its global prevalence and significant health care burden. The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson Disease program was established to promote discovery of potential therapies.

Link to article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349346/

PubMed:  https://pubmed.ncbi.nlm.nih.gov/25668262/

Authors: Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators; Karl Kieburtz, Barbara C Tilley, Jordan J Elm, Debra Babcock, Robert Hauser, G Webster Ross, Alicia H Augustine, Erika U Augustine, Michael J Aminoff, Ivan G Bodis-Wollner, James Boyd, Franca Cambi, Kelvin Chou, Chadwick W Christine, Michelle Cines, Nabila Dahodwala, Lorelei Derwent, Richard B Dewey Jr, Katherine Hawthorne, David J Houghton, Cornelia Kamp, Maureen Leehey, Mark F Lew, Grace S Lin Liang, Sheng T Luo, Zoltan Mari, John C Morgan, Sotirios Parashos, Adriana Pérez, Helen Petrovitch, Suja Rajan, Sue Reichwein, Jessie Tatsuno Roth, Jay S Schneider, Kathleen M Shannon, David K Simon, Tanya Simuni, Carlos Singer, Lewis Sudarsky, Caroline M Tanner, Chizoba C Umeh, Karen Williams, Anne-Marie Wills

Key Terms: Non-CCDS disease, General Creatine, Supplements, Clinical Study, Pediatric Patient, Adult Patient, Male + Female Patients